Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.
第一作者:
G,Cebers
第一单位:
Clay W. Scott, PhD, AstraZeneca, Drug Safety and Metabolism, 35 Gatehouse Ln, Waltham, MA 02451. Phone: 781-472-5124, Email: clay.scott@astrazeneca.com.
作者:
DOI
10.14283/jpad.2016.119
PMID
29199322
发布时间
2019-11-20
- 浏览4
The journal of prevention of Alzheimer's disease
2016年3卷4期
202-218页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



